You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-NFkB p65 antibody [NF-12] (ab10437)

Submit an Abreview Q&A (3)

Overview

  • Product nameAnti-NFkB p65 antibody [NF-12]See all NFkB p65 primary antibodies ...
  • Description
    Mouse monoclonal [NF-12] to NFkB p65
  • SpecificityThis antibody recognizes an epitope within the C-terminal region of the mouse NF-kappaB p65.
  • Tested applicationsWB, ICC more details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Recombinant, mouse NF-kB p65 fragment (C-terminal 151 amino acids).

Properties

Applications

Our Abpromise guarantee covers the use of ab10437 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
WB
ICC
  • Application notesICC: Use at an assay dependent dilution.
    WB: Use at an assay dependent dilution. Detects a band of approximately 65 kDa (predicted molecular weight: 65 kDa).

    A minimum working dilution of 1/1000 is determined by immunoblotting using a whole cell extract of 3T3 mouse fibroblast cells.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.

    • Target

    • FunctionNF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1.
    • Sequence similaritiesContains 1 RHD (Rel-like) domain.
    • Domainthe 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.
    • Post-translational
      modifications      Ubiquitinated, leading to its proteasomal degradation. Degradation is required for termination of NF-kappa-B response.
      Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes the formation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity. Phosphorylation at Ser-311 disrupts the interaction with EHMT1 without preventing monomethylation at Lys-310 and relieves the repression of target genes.
      Phosphorylation at Ser-311 disrupts the interaction with EHMT1 and promotes transcription factor activity (By similarity). Phosphorylation on Ser-536 stimulates acetylation on Lys-310 and interaction with CBP; the phosphorylated and acetylated forms show enhanced transcriptional activity.
      Reversibly acetylated; the acetylation seems to be mediated by CBP, the deacetylation by HDAC3. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA. Acetylation at Lys-310 is required for full transcriptional activity in the absence of effects on DNA binding and NFKBIA association. Acetylation can also lower DNA-binding and results in nuclear export. Interaction with BRMS1 promotes deacetylation of 'Lys-310'.
    • Cellular localizationNucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B). Colocalized with RELA in the nucleus upon TNF-alpha induction.

      • Target information above from: UniProt accession Q04206 The UniProt Consortium
      The Universal Protein Resource (UniProt) in 2010
      Nucleic Acids Res. 38:D142-D148 (2010) .

      Information by UniProt
    • Database links
      • Alternative names
          Avian reticuloendotheliosis viral (v rel) oncogene homolog A antibodyMGC131774 antibodyNF kappa B p65delta3 antibody
          NFKB 3 antibodyNFKB3 antibodyNuclear Factor NF Kappa B p65 Subunit antibodyNuclear factor NF-kappa-B p65 subunit antibodyNuclear factor of kappa light polypeptide gene enhancer in B cells 3 antibodyNuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B Cells antibodyNuclear factor of kappa light polypeptide gene enhancer in B-cells 3 antibodyOTTHUMP00000233473 antibodyOTTHUMP00000233474 antibodyOTTHUMP00000233475 antibodyOTTHUMP00000233476 antibodyOTTHUMP00000233900 antibodyp65 antibodyp65 NF kappaB antibodyp65 NFkB antibodyRELA antibodyTF65_HUMAN antibodyTranscription Factor p65 antibodyv rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B cells 3 (p65)) antibodyV Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A antibodyv rel reticuloendotheliosis viral oncogene homolog A (avian) antibodyV rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B cells 3, p65 antibodyv-rel reticuloendotheliosis viral oncogene homolog A antibody
        see all

      References for Anti-NFkB p65 antibody [NF-12] (ab10437)

      ab10437 has not yet been referenced specifically in any publications.

      Publishing research using ab10437 ? Please let us know so that we can cite the reference in this datasheet

      Product Wall

      Submit an Abreview for ab10437 Submit a Question for ab10437

      Displaying 1 - 3 of 3 results for Abreviews and Q&A

      10
      Votes: Highest First

      Email: vvachhar@wfubmc.edu Is this product safe for use in live animals?

      Thank you for your enquiry. This antibody (ab10437) contains sodium azide preservative, so is not suitable for use in vivo. I am sorry this is not the news you probably needed. If you have any more questions please don't hesitate to get back to me. I ...

      Read More

      The volume of this product states 50ul, but there is no mention of the concentration. Do you have a concentration, even if estimated, for this product?

      Thank you for your enquiry. This antibody is provided in an unpurified form, ascites, and we cannot guarantee the concentration for unpurified material. However, given that it is ascites it is estimated to be between 2 and 10 mg/ml. If you have any ...

      Read More

      I would like to know the preservative of #ab10437. According your website, it contains 15% Sodium azide. But it seems to be too much. Is it right? Please advise.

      Thank you for your enquiry. We would like to confirm that the concentration of sodium azide is 15 mM. We have updated the datasheet. Thank you for bringing this matter to out attention.

      Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"